

**EMORY UNIVERSITY SCHOOL OF MEDICINE
CURRICULUM VITAE**

Revised: 5/8/2019



1. Name: Karen Patricia Mann, M.D., Ph.D.

2. Office Address:

Medical Director of Clinical Laboratory and
Chief of Clinical Pathology
Grady Health System
Laboratory Administration
80 Jesse Hill Jr Drive SE
1st Floor - Room 1G053
Atlanta, GA 30303

Tel: (404) 616-4800

3. E-mail Address: kmann@emory.edu

4. Citizenship: USA

5. Current Titles and Affiliations:

a. Academic Appointments:

Primary appointments:

Professor, Clinical Track 9/1/2011 - current
Emory University School of Medicine
Department of Pathology and Laboratory Medicine
Atlanta, GA

b. Clinical Appointments:

Medical Director of Clinical Laboratory
Chief of Clinical Pathology
Medical Director of Hematology, Special Hematology and Coagulation
Grady Health System
Atlanta, GA

Medical Director of Clinical Laboratory
Kirkwood Neighborhood Clinic
Grady Health System

Medical Director of Clinical Laboratory
Camp Creek Comprehensive Care Clinic.
Grady Health System

Medical Director of Clinical Laboratory
Hughes Spalding Laboratory

6. Previous Academic and Professional Appointments:

Associate, Department of Pathology, Duke University Medical Center
Durham, NC, 2/1994-6/1994

Assistant Professor, Department of Pathology, Duke University Medical Center, Durham,
NC, 7/1994-6/1999

Assistant Professor, Department of Pathology and Laboratory Medicine Emory University
School of Medicine, 7/1999-12/1999

Associate Professor, Department of Pathology and Laboratory Medicine Emory University
School of Medicine, 1/2000-8/2011

7. Previous Administrative Appointments:

Director, Hematopathology Section 2/1/2013 – 4/31/2015
Director, Molecular Hematopathology Laboratory 7/1/1999 - 4/31/2015

Director, Hematopathology Training Program, Department of Pathology
Duke University Medical Center, 8/1997-6/1999

Director, Section of Hematopathology, Department of Pathology
Duke University Medical Center, 8/1997-6/1999

Director Clinical Flow Cytometry Laboratory, Department of Pathology
Duke University Medical Center, 8/1997-6/1999

Director, Molecular Genetic Pathology Fellowship, 7/2002 – 6/2017
Emory University School of Medicine

8. Licensures/Boards:

Georgia Medical License issued 7/1999
North Carolina Medical License issued 6/2/1992
NBME: Part 1 – 6/1983
Part 2 – 9/1997

9. Specialty Boards:

American Board of Pathology Certifications:
Anatomic Pathology, Georgia, issued 11/2/1993
Hematopathology, Georgia, issued 8/13/1997
Molecular Genetic Pathology, Georgia, issued 9/22/2003

10. Education:

<u>Year</u>	<u>Degree</u>	<u>Institution</u>
1976-1978		University of Massachusetts Amherst, MA
1978-1980	A.B., Magna cum laude	Harvard University Boston, MA
1981-1988	M.D, Ph.D.	Tufts University School of Medicine Sackler School of Graduate Studies Boston, MA PhD Advisor: David Thorley-Lawson, Ph.D.

11. Postgraduate Training:

7/1988-6/1989	Internship, Department of Pathology, Duke University Medical Center Durham, NC
7/1989-6/1993	Residency (Anatomic Pathology), Department of Pathology, Duke University Medical Center, Durham, NC
10/1989-6/1992	Molecular Biology Research Fellow, Duke University Medical Center Durham, NC Supervisor: Joseph Nevins, Ph.D., Howard Hughes Institute
7/1993-1/1994	Hematopathology Fellow, Department of Pathology, Duke University Medical Center, Durham, NC, Supervisors: Michael Borowitz, M.D., Ph.D. and Howard Ratech, M.D.
2/2014-1/2015	The Business of Healthcare Elective Series—Goizueta Executive MBA (EMBA) Healthcare Seminar Cycle, 8 Credit hours
1/2017	Learning to Be Better Teachers -- Office of Faculty Affairs and Professional Development, Emory University School of Medicine, Atlanta, GA, 1 day workshop (6.75 CME)

12. Committee Memberships:

a. National and International:

Association of Molecular Pathology:

Chair-elect, Hematopathology Subdivision, 2002

Chair, Hematopathology Subdivision, 2003

Program Committee, 1/2002 – 12/2003

Nominations Committee, 1/2004 – 12/2005

Publications Committee, Chair, 1/2006 – 12/2007

Member of Council and Secretary Treasurer, 1/2006 – 12/2007

Professional Relations Committee, 11/1/2008-11/1/2009

Liaison to the Strategic Planning Committee, 2009

President-elect, 2009

Member of Council, 2009-2011

Member of Professional Services Oversight Committee, 2009 – 2011
President, 2010

Member of Budget and Finance Committee, 2010 – 2011

Past-President, 2011

Nominations Committee, Chair 2011

Strategic Planning Steering Committee, Chair 2011

Strategic Planning Implementation Committee, Chair 2011

Whole Genome Analysis Working Group, member 2010 – 11/2014

Nominations Committee, Hematopathology Representative, 2014-2015

Society of Hematopathology:

Review of Member Survey, Ad Hoc Committee, 2009

American Society of Hematology:

Scientific Subcommittee on Hematopathology and Laboratory Hematology, 2011-2015

Chair-elect 2013

Chair 2014

Myeloproliferative Disease International Research Consortium:

Disorders Research Consortium Investigator (MPD-RC) 2008 – current

Hematologic Malignancies Research Consortium:

Member, 2010 - current

American Board of Pathology

Member, Molecular Genetic Pathology Test Development and Advisory Committee. 2019 – current.

b. Institutional:

Department of Pathology, Molecular Pathology Advisory Committee, 1998 - 6/1999

Department of Pathology and Laboratory Medicine, Faculty Accountability Committee, 7/2000 - 12/2000

Winship Cancer Center Cancer Committee, 3/2001-9/2010

Quality Improvement Subcommittee, Director, 1/2005 – 9/2010

Pathology, Billing Committee Member, 7/2003- 2012;

Chair, 5/2006 – 2012

Anatomic Pathology, Ad Hoc Retreat Planning Committee, 2003

Hospital Charge Lag reporting committee, Faculty Liaison, 5/2006 – 2012

Clinical and Predictive Health Subcommittee, Functional and Space Program for the Clifton and Midtown Redevelopment Project, Pathology Representative, 6/2007 – 12/2007

Emory Healthcare Functional Space Planning Group, Clinical Research & Predictive Health Programming Group, 2007

Clinical Pathology Retreat Planning Committee, Co-chair of Clinical Service Group, 2007

Clinical Molecular Testing Utilization Committee, Subcommittee of Emory University Hospital and Emory University Hospital Midtown Medical Practice Committee, Co-chair, 2008-2015

Anatomic Pathology Retreat Planning Committee, Co-chair of Community and Integration Subcommittee, 10/2009 – 5/2010

Anatomic Pathology Leadership Advisory Committee, 7/2010 – 2013

Winship Cancer Institute of Emory University, Discovery and Developmental Therapeutics Research Program Member, 09/2011 – current

Next Generation Sequencing Implementation Committee, 03/2013 – 2014

Pathologist consultant, Emory Winship Cancer Institute Bone Marrow and Blood Stem Cell Transplant Program, 2013- current

Medical Executive Committee, Grady Health System, 2015-current

Physician Credentialing Committee, Grady Health System, 2015-current

Transfusion Medicine Committee, Grady Health System, 2015-current

Anatomic Pathology Quality Improvement Committee, Grady Health System, 2015-current

Quality Improvement Committee, Grady Health System, 2015-current

ECC Laboratory Task force, Grady Health System, 2015-current

Blood and Laboratory Utilization committee, Grady Health System, 2018-current

Clinical Pathology Subcommittee Meeting, Emory University Department of Pathology and Laboratory Medicine, 8/2018 – current.

13. Manuscript reviewer:

- a. *Cancer*, ad hoc reviewer
- b. *American Journal of Pathology*, ad hoc reviewer
- c. *The Journal of Molecular Diagnostics*, ad hoc reviewer since 2006
- d. *American Journal of Clinical Pathology*, ad hoc reviewer
- e. *Head and Neck Pathology*, ad hoc reviewer since 2006
- f. *Expert Review of Molecular Pathology*, ad hoc reviewer
- g. *Haematologica*, ad hoc reviewer

14. Editorships and Editorial Boards:

Journal of Molecular Diagnostics, 2012-current

15. Honors and Awards:

National Science Foundation Undergraduate Research Fellowship, 1979

National Research Service Postdoctoral Fellowship Award, NIH, 1990

16. Society Memberships:

United States and Canadian Academy of Pathology, Member, 1993 – current

Clinical Cytometry Society, Member, 1994 – 2002

International Society for Analytical Cytology, Member, 1996 – 2002

CALGB Hematopathology Committee, Member, 1996 – 1999

Society for Hematopathology, Member, 1997 – current

North Carolina Medical Society, Member, 1997 – current

American Society of Hematology, Member, 1999 – current

Association for Molecular Pathology, Member, 1999 – current

College of American Pathologists, Member, 2009 – current

International Society for Laboratory Hematology, 2017 – current

International Clinical Cytometry Society, 2017- current

17. Organization of Conferences:

a. National or International

i. Administrative positions:

Association for Molecular Pathology:

Chair-elect, Hematopathology Division, 1/1/2002 - 12/31/2002

Program Committee, 1/1/2002 - 12/31/2003

American Society of Hematology:

Chair, Scientific Subcommittee for Hematopathology and Laboratory Hematology, 2014

Chair-elect 2013, Member 2011-2014

ii. Sessions as chair:

Association for Molecular Pathology:
Chair, Hematopathology Division, 1/1/2003 - 12/31/2003

American Society of Hematology
Chair, Scientific Subcommittee for Hematopathology and Laboratory
Hematology, 12/2014

18. Clinical Service Contributions:

Duke University Medical Center:

Implementation of use of flow cytometric immunophenotyping in tissue samples, 1994.

Coordinated implementation of reporting of flow cytometric results into hospital information System so that clinicians can look up reports electronically, 1997.

Coordination of integration of flow cytometric immunophenotyping results into integrated morphology/molecular/flow cytometric report of hematopoietic malignancies, 1997.

Improvement of hematopathology service and resident teaching by decreasing clerical type work:

Implementation of use of technical staff, couriers and pneumatic tube system for collection and delivery of slides formerly organized by residents, 1996.

Development and implementation of template and speed write phrases to facilitate dictation and decrease need for corrections in reports, 1997-1999.

Coordinated development of automatic printing of CBC/SPEP/IFE/LDH laboratory values for hematopathology cases, 1998.

Implementation of 4-color flow cytometric immunophenotyping on clinical samples, 1998

Emory University:

Integration of molecular hematopathology diagnostic services in routine hematopathology diagnostic sign-out, 2000

Integration of molecular hematopathology results into an integrated morphology/flow cytometry molecular report – 5/2001

Implementation of use by capillary gel electrophoresis in molecular diagnostic testing for T cell receptor gamma gene rearrangement, 10/2001
Development of ACGME accredited Molecular Genetic Pathology Fellowship Program, 2001

Implementation of use of fragment analysis capillary gel electrophoresis in molecular diagnostic testing for B cell gene rearrangement, 1/2002

Implementation of a real time PCR test to detect the *BCL2-IGH* translocation seen in follicular lymphoma, 7/2002

Implementation of a quantitative RT-PCR test to detect and monitor the level of *BCR-ABL* mRNA product seen in chronic myelogenous leukemia and precursor B-cell acute lymphoblastic leukemia, 3/2003

Implementation of a quantitative RT-PCR test to detect and monitor the level of the *PML-RARA* mRNA product seen in acute promyelocytic leukemia, 2004

Implementation of PCR testing for *JAK2* point mutations in chronic myeloproliferative disorders, 2006

Implementation of PCR testing for *FLT3* mutation in acute myeloid leukemia

Implementation of PCR testing for *NPM1* mutation in acute myeloid leukemia

Oversee verification and implementation of use of Analyte Specific Reagents for PCR testing for *FLT3* mutation testing, *IGH* gene rearrangement testing and *TCR* gene rearrangement testing.

Organization and development of the Clinical Molecular Testing Utilization Committee for evaluating evidence of basis of novel molecular testing

Oversee validation of kappa and kappa deleted element gene rearrangement evaluation.

Oversee validation of BCR-ABL1 international quantitation standard

Member of group responsible for implementation of microarray and next-generation sequencing implementation

Grady Health System

Oversee validation of Aquios flow cytometers for lymphocyte subset analysis

Oversee validation of Sebia Capillaries for Hemoglobin electrophoresis

Implement use of Bone marrow drill for bone marrow aspirate and biopsies in conjunction with Hematology Oncology

Oversee ongoing validation of leukemia/lymphoma flow cytometric immunophenotyping

Engaged in collaboration with Danaher consultants to develop Lean Daily Management program in Grady Medical Laboratory

Oversee opening of Clinical Laboratory at Camp Creek Comprehensive Care Center.

Oversee verification of new HIT test in Coagulation laboratory.

19. Formal Teaching:

a. Medical Student Teaching:

Pathology 200 (Core Course), Duke University Medical Center

- Assistant, laboratory section, 50 hours, 1993
- Diseases of the Blood, Bone Marrow and Lymph Nodes, 3 x 1-hour lectures/year, 1998-1999
- Clinical Pathologic Correlation, Acute Promyelocytic Leukemia, 1 hour/year Multidisciplinary Presentation, 1997-1999

Pathology 241B (Surgical Pathology Lecture Series), Duke University Medical Center

- Classification of lymphomas, 1 hour/year, 1994-1998
- Splenic Pathology, 1 hour/year, 1999
- Leukemia classification, from FAB to WHO, 1 hour/year, 1999

Oncology as a Basic Science, Rad Onc 211 (medical school elective), Duke University Medical Center

- Immunohistochemistry in Oncology, 1 hour/year, 1995-1997

b. Graduate Program:

Residency program:

Pathology 241B (Surgical Pathology Lecture Series), Duke University Medical Center

- Classification of lymphomas, 1 hour/year, 1994-1998
- Splenic pathology, 1 hour/year, 1999
- Leukemia classification, from FAB to WHO, 1 hour/year, 1999

Pathology 225 (Introduction to Systemic Histology), Duke University Medical Center

- Histology of bone marrow, lymph nodes and spleen, 3 hours, 1997

Hematology/Oncology Gallops Conference, Duke University Medical Center, CME-accredited weekly conference for hematology-oncology fellows, residents and attending staff, with monthly pathology presentations. Responsible for directing resident and fellow pathology presentations. Monthly 1-hour conference, 1994-1999

Hematology/Oncology Tumor Board, Duke University Medical Center, CME-accredited

multidisciplinary conference for attending physicians and hematology/oncology fellows, responsible for presenting pathology findings on all new lymphoma patients. Weekly 1-hour conference, 1997-1999

Pediatric Hematology/Oncology Bone Marrow Aspirate Review, Duke University Medical Center, weekly conference for pediatric hematology/oncology fellows, responsible for reviewing all pediatric bone marrow aspirations and biopsies. Weekly 1-hour conference, 1997-1999

Pediatric Hematology/Oncology Tumor Board, Duke University Medical Center, CME-accredited multidisciplinary conference for pediatric hematology/oncology fellows, staff and attending physicians. Responsible for coordinating pathology presentation. Responsible for presentation of hematopathology cases. Monthly 1-hour conference, 1997-1999.

Clinical Pathology Core Lecture Series. Emory University Hospital, Teaching Conference for all CP residents. Presented 3 x 1 hour lectures on Lymphoid Pathology, 2000, 2002, 2004, 2006.

Clinical Pathology Core Lecture Series. Emory University Hospital, Teaching Conference for all CP residents. Presented 2 x 1 hour lectures on Molecular Hematopathology, 2008, 2010, 2012, 2013.

Pediatric Hematology/Oncology Tumor Board, Children's Hospital of Atlanta, Multidisciplinary conference for pediatric hematology/oncology fellows, staff and attending physicians. Share responsibility for presenting hematopathology cases. Monthly 1-hour conference, 1999-2008.

Hematology Oncology Fellow Didactic Session. One hour lecture to the Emory Hematology Oncology fellows on the topic of Molecular Pathology. 8/18/2010.

c. Other Categories:

Medical technologist school, Hematopathology course
Special stains 2008-2009
CLL and other lymphoproliferative disorders 2010-2012

20. Supervisory Teaching:

a. Post-doctoral fellows directly supervised (and current position):

Katharine Liu, M.D., Pathologist, Wilmington Pathology Associates, Wilmington, NC

Filiz Sen, M.D., Pathologist, Memorial Sloan Kettering, New York, NY

Antonio Subtil, M.D., Associate Professor, Dermatology and of Pathology, Yale University, New Haven, CT

Charles Hill, M.D., Ph.D., Associate Professor, Emory University Dept. of Pathology

Azita Djalilvand, MD, Myriad Genetics, Salt Lake City, UT

Anurhadna Radhakrishnan, MD, Pathologist, Quest Diagnostics, GA

Arshad Ahsannudin, MD, Assistant Professor, Dept. of Pathology, University of Manitoba, Winipeg, Canada

Justin Cole, MD, PhD, Pathologist, Compass Oncology, Vancouver, WA

Christine Schmotzer, MD, Assistant Professor and Director of Clinical Chemistry, Case Medical Center, Cleveland OH

Cynthia McCloskey, MD, Assistant Professor, Dept. of Pathology, University of Oklahoma, Oklahoma City, OK

Deborah Spencer, MD, Associate Pathologist at Integrated Regional Laboratories- HCA Physician Services Fort Lauderdale, FL

Ruan Ramjit, MD, Kaiser Permanente/the Southern California Permanente Medical Group, Los Angeles, CA

Linsheng Zhang, MD, PhD, Assistant Professor, Emory University Department of Pathology and Laboratory Medicine

Jason Wang, MD, Assistant Professor, Department of Pathology, UT Southwestern Medical Center, Dallas, TX.

Kevin Fisher, MD, PhD, Assistant Professor, Department of Pathology, Texas Children's Hospital, Houston, TX

Christina Appin, MD, Assistant Professor, Department of Pathology, Northwestern University, Chicago, IL

Thomas Schneider, MD, Emory Genetics Laboratory, Atlanta, GA¶

Adrian Box, MD, ¶University Hospital, Edmonton, Alberta, Canada

Michael Clay, MD, Assistant Member, St. Jude Faculty, St Jude Children's Research Hospital, Memphis, TN

Omid Roudh, MD, Molecular Genetic Pathology Fellow, Emory University Department of Pathology and Laboratory Medicine

Tong Yang, MD, Molecular Genetic Pathology Fellow, Emory University Department of Pathology and Laboratory Medicine

Melanie Wooten, MD, Hematopathology Fellow, Emory University Department of Pathology and Laboratory Medicine

b. Residency Program:

Director of Hematopathology Fellowship Program, Duke University Medical Center 1997-1999. Responsible for all administrative duties relating to hematopathology fellowship program, including fellow selection and training, ACGME and internal accreditation of program teaching and advising of fellows.

Hematopathology resident training:

Responsible for resident and fellow training in hematopathology and flow cytometry:

1994-1997: Shared responsibility for resident training in morphologic evaluation of peripheral blood smear, bone marrow aspirations and biopsies, lymph node biopsies and spleens. Shared responsibility in training, in incorporating ancillary techniques, in hematopathology (molecular diagnostics, cytogenetics, and immunohistochemistry).

1997-1999: Director of hematopathology section. Directed residency rotations in hematopathology (1-3 month rotation). Primarily responsible for resident training in hematopathology, including ancillary techniques.

1994-1999: Director of Clinical Flow Cytometry Laboratory. Responsible for resident training in use of an interpretation of flow cytometric studies including lymphoma and leukemia phenotyping and lymphocyte enumeration assays.

Emory University Hospital:

1999-2015: Responsible for resident and fellow training in Molecular Hematopathology.

1999-2015: Share responsibility for training residents and fellows in diagnostic hematopathology, FISH, cytogenetics and flow cytometry.

2002-current: Director, Molecular Genetic Pathology Fellowship

2011- 2015: Share responsibility for implementation of new Molecular Pathology Curriculum.

Grady Health System:

2015- current: Responsible for Grady Hematopathology rotation, with focus on non-neoplastic hematopathology

2015 – current: Responsible for Laboratory Administration /Benign Hematology rotation.

2015- current: Oversee Clinical Pathology Elective

c. Other:

Visiting residents, Molecular Pathology Rotation

Dahui Qin, M.D., Ph.D., 12/2003.

Xuebin Yang, M.D., 2/2013

21. Lectureships, Seminar Invitations, and Visiting Professorships:

Emory University Hospital, Atlanta, GA. Polyadenylation of pre-mRNA, mechanism and regulation of gene expression, 1993

Expression of CD6 and CD6L (ALCAM) in hematopoietic neoplasms. Presented at:

Clinical Applications in Cytometry Meeting, Charleston, SC, 1996

University of Rochester, Rochester, NY, 1998

University of Florida, Gainesville, FL, 1998

Emory University Hospital, Atlanta, GA, 1999

Emory University Hospital, Atlanta, GA. Leukemia and lymphoma classification, Hematology-Oncology Grand Rounds, 2/1/2000

Emory University Hospital, Atlanta, GA. Hepatosplenic gamma-delta T-cell lymphoma, Inter-institutional Pathology Slide Seminar, 2/15/2000

Emory University Hospital, Atlanta, GA. Sequential/Composite Lymphomas, Faculty, Diagnostic Problems in Surgical Pathology, 10/7/2000

Emory University Hospital, Atlanta, GA. Extramedullary Myeloid Tumor, Faculty, Diagnostic Problems in Surgical Pathology, 10/6/2001.

Diagnostic Problems in Anatomic and Clinical Pathology, Sheraton Buckhead Hotel, Atlanta, GA, Angioimmunoblastic T-cell lymphoma. Faculty, 10/19-20/2002

Molecular Hematopathology, Faculty, Diagnostic Problems in Anatomic and Clinical Pathology, Crown Plaza Hotel, Atlanta, GA, 10/19/2003.

William Beaumont Hospital 14th Annual Symposium on Molecular Pathology DNA Technology in the Clinical Laboratory, Detroit, MI, BCR/ABL Q-PCR testing and CML, 9/16/2005.

Molecular Hematopathology, Faculty, Diagnostic Problems in Anatomic and Clinical Pathology, Intercontinental Hotel Buckhead, Atlanta, GA, 10/9/2005.

Molecular Hematopathology, Faculty, Diagnostic Problems in Anatomic and Clinical Pathology, Atlanta, GA, 10/9/2006.

Molecular Hematopathology, Faculty, Diagnostic Problems in Anatomic and Clinical Pathology, Marietta, GA, 10/6/2007.

Molecular Hematopathology, Myeloid Neoplasms and Lymphoid Neoplasms, Faculty, Molecular Pathology Essentials: Principles and Practice, Baltimore, MD, 5/13/2008.

CML, Past, Present and Future, Department of Pathology and Laboratory Medicine Grand Rounds at the Weill Cornell Medical College, New York, NY, 1/26/2009.

Update in Myeloid Neoplasms, WHO cares? Diagnostic Problems in Anatomic and Clinical Pathology, Atlanta, GA, 4/18/2009.

Update in Myeloid Neoplasms, WHO cares? Pathology Grand Rounds, Gwinnett Medical Center, Lawrenceville, GA, 4/22/2009.

Myeloid Neoplasms. AMP-AACC Molecular Pathology Essentials, Copenhagen, Denmark, 10/2/2009.

Hematologic Neoplasms. AMP-AACC Molecular Pathology Essentials, Atlanta, GA, 5/18/2010.

22. Invitations to National/International, Regional, and Institutional Conferences:

ASCP Teleconference, 2001. Body Fluid Specimens in the Clinical Laboratory: Selected Cases, April 24, 2001.

Association for Molecular Pathology, 2002. *BCR-ABL* Quantitation, an Interlaboratory Comparison, Adams Mark Hotel, Dallas, TX, November 15, 2002.

Association for Molecular Pathology, 2004. *BCR-ABL* Quantitative Real Time PCR Sample Exchange, Westin Century Plaza Hotel, Los Angeles, California, November 11-13, 2004.

The National Program of Cancer Registries (NPCR) at the Centers for Disease Control and Prevention, and the Surveillance, Epidemiology, and End Results (SEER) Program at the National Cancer Institute (NCI) conference on current issues in the hematopoietic and lymphoid diseases, 2007, Atlanta, GA, July 9-11, 2007.

Educational Workshop on Clonality Assessment, Nijmegen, the Netherlands, 2/8-2/10/2010.

Molecular Medicine Tri-Conference, San Francisco, CA. How gene patents affect the clinical laboratory and patient care. Speaker and panelist in, IP ISSUES ON GENE PATENTING: What is the Solution? February 3-5, 2010.

Banbury Conference on Genome Era Pathology, Precision Diagnostics and Preemptive Care: A Stakeholder Summit, invited participant, October 13-15, 2010.

The Future of Pathology in Personalized Medicine – A Stakeholder Summit, invited participant, May 23-24, 2011.

International Conference of the Jordanian Society of Pathology, Molecular Pathology of lymphoid neoplasms, an update, and, the good, the bad and the ugly in Molecular Pathology, Keynote speaker, 4/2011.

Molecular Pathology of Myeloid Neoplasms, AGT 37th Annual Meeting, Association of Genetic Technologist, Atlanta, GA, 6/7/2012.

IAP Congress, Bangkok, Thailand, Molecular case presentation, 10/7/2014.

IAP Congress, Bangkok, Thailand, NGS, Magic bullet or just another lab test? 10/8/2014.

American Society of Hematology Annual Meeting, Moderator, Myelodysplastic Syndromes: Beyond the Karyotype and Blast Count, Scientific Subcommittee Sessions, 12/6/2014 & 12/7/2014

Other Activities:

CAP inspector and Team leader with Molecular Pathology and Flow cytometry certification.

Faculty panelist in Career seminar panel for pathology residents at Emory University, Atlanta, GA, 2/2010 and 3/3013

AMP representative at National Pathology Organizations Meeting, Bethesda, MD, 1/29/10

External Perspective on NIST's Measurement Services: Impacts and Issues – Panel Presentations Invited speaker and AMP representative at National Institute of Standards and Technology, Visiting Committee on Advanced Technology, Gaithersburg, MD, 6/9/10.

Session 2: Clinical Laboratory Challenges, invited panelist, FDA Public Meeting on Oversight of Laboratory Developed Tests, Hyattsville, MD, July 19, 2010.

Invited Member, The Joint Commission Molecular Methods Technical Advisory Panel, 2019

23. Research Focus:

Molecular diagnosis of neoplastic hematolymphoid disorders

Development of clinical genomic testing in oncology

24. Grant Support:

Previous support:

1. Federally Funded:

National Research Service Award. Postdoctoral fellowship in the laboratory of Dr. Joseph Nevins. March 1990 - February, 1992.

2. Private Foundation Funded:

Co-investigator: "Pilot study to evaluate the effects of cytotoxic chemotherapy with combination antiretroviral therapy in HIV infected individuals with non-Hodgkin's Lymphoma," PI: G.D. Miralles. July 1996 – June 1999.

Co-investigator: "A phase I research study of cellular adoptive immunotherapy using Epstein-Barr Virus (EBV)-specific T-cells (EBV killer T cells) in HIV infected individuals with previously untreated EBV associated b-cell lymphoma who fail CHOP chemotherapy," PIs: H.K. Lyerly & C. Smith. May 1997-1998.

3. Pilot grant, Winship Cancer Institute:

Co-investigator: "Diagnostic Test for Renal Cell Carcinoma", 2/2014 – 2016.

Current:

1. Federally Funded:

Sub-investigator: "The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study," Emory PI: Christopher Flowers, MD, NIH, 6/23/15 - 5/31/20, 2% support

25. Bibliography:

a. Published and accepted research articles (clinical, basic science, other) in refereed journals:

1. Klyce SD, Palkama KA, Harkonen M, Marshall WS, Huhtaniitty S, **Mann KP**, Neufeld AH. 1982. Neural serotonin stimulates chloride transport in the rabbit corneal epithelium. Invest Ophthalmol Vis Sci 23:181-192, Aug.
2. **Mann KP**, Staunton D, Thorley-Lawson DA. 1985. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J. Virol 55: 710-720, Sep.
3. Thorley-Lawson DA, **Mann KP**. 1985. Early events in Epstein-Barr virus infection provide a model for B cell activation. J Exp Med 162:45-59, Jul.
4. Tischler AS, Mobtaker H, **Mann KP**, Nunnemacher G, Jason WJ, Dayal Y, Delellis RA, Adelman L, Wolfe HJ. 1986. Anti-lymphocyte antibody Leu-7 (HNK-1) recognizes a constituent of neuroendocrine granule matrix. J Histochem Cytochem 34:1213-1216, Sep.

5. **Mann KP**, Thorley-Lawson DA. 1987. Posttranslational processing of the Epstein-Barr virus-encoded p63/LMP protein. *J Virol* 61:2100-2108, Jul.
6. **Mann KP**, Weiss EA, Nevins JR. 1993. Alternative poly(A) site utilization during adenovirus infection coincides with a decrease in the activity of a poly(A) site-processing factor. *Mol Cell Biol* 13:2411-2419, Apr.
7. **Mann KP**, Hall B, Kamino H, Borowitz MJ, Ratech H. 1995. Neutrophil-rich Ki-1 positive anaplastic large cell malignant lymphoma. *Amer J Surg Pathol* 19:407-416, Apr.
8. Horvatinovich JM, Sparks SD, **Mann KP**. 1996. Establishing a pure lymphocyte gate for subset analysis by flow cytometry. *Cytometry* 26:172-177, Jun.
9. Bottom KS, Adams DM, **Mann KP**, Ware RE. 1997. Trilineage hematopoietic toxicity associated with valproic acid therapy. *J Pediatric Hematology Oncology* 19:73-76, Jan-Feb.
10. **Mann KP**, DeCastro CM, Liu J, Moore JO, Bigner SH, Traweek ST. 1997. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. *Am J Clin Pathol* 107:653-660, Jun.
11. Liu K, Coogan AC, **Mann KP**. 1998. Fine needle aspiration of large cell lymphoma in a patient with agnogenic myeloid metaplasia: a case report and review of the literature. *Diagn Cytopathol* 19:205-209, Sep. [Review]
12. Perry BP, Gregg CM, Myers S, Lilly S, **Mann KP**, Prieto V. 1998. Rosai-Dorfman disease (extranodal sinus histiocytosis) in a patient with HIV. *Ear, Nose, & Throat Journal* 77:855-858, Oct.
13. Liu K, **Mann KP**, Garst JL, Dodd LG, Olatidoye BA. 1999. Diagnosis of post-transplant granulocytic sarcoma by fine needle aspiration cytology and flow cytometry. *Diagn Cytopathol* 20:85-89, Feb.
14. Murray CK, Estey E, Paietta E, Howard RS, Pierce S, Edenfield WJ, **Mann KP**, Bolan C, Byrd JC. 1999. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? *J Clin Oncol* 17: 293-297, Jan.
15. Lin WC, Moore JO, Traweek ST, **Mann KP**, Smith C. 1999. Post transplant CD8+ gamma delta T-cell lymphoma associated with human herpes virus-6 infection. *Leuk Lymphoma* 33:377-384, Apr. [Review]
16. Liu K, **Mann KP**, Vitellas KM, Paulson EK, Nelson RC, Gockerman JP, Dodd LG. 1999. Fine needle aspiration with flow cytometric immunophenotyping for primary diagnosis of intra-abdominal lymphomas. *Diagn Cytopathol* 21:98-104, Aug.
17. Morphew E, Nuckols JD, **Mann KP**, Howell DN, Robboy SJ, Stenzel TT. 1999.

Evaluation of an automated technique for identification of extraneous tissue in formalin-fixed surgical specimens. *Lab Invest* 79:1135.

18. Qumsiyeh MB, Cheng C, Eyre J, **Mann KP**, Zhang XX. 2000. Tetrasomy 8 evolving into a segmental triplication 8q in a case of acute monocytic leukemia. *Cancer Genetics Cytogenetics* 116:74-76, Jan.
19. Liu K, Stern RC, Rogers RT, Dodd LG, **Mann KP**. 2001. Diagnosis of hematopoietic processes by fine-needle aspiration in conjunction with flow cytometry: A review of 127 cases. *Diagn Cytopathol* 24:1-10, Jan.
20. Sen F, **Mann KP**, Medeiros LJ. 2002. Multiple myeloma in association with sarcoidosis: A case report and review of the literature. *Arch Pathol Lab Med* 126:365-368, Mar. [Review]
21. Juco J, Holden JT, Kelly LG, **Mann KP**, Li S. 2003. Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry. *Am J Clin Pathol* 119:205-212, Feb.
22. Li S, **Mann KP**, Holden JT. 2004. T-cell-rich B-cell lymphoma presenting in the spleen: a clinicopathologic analysis of 3 cases. *Int J Surg Pathol* 12:31-37, Jan.
23. Li S, Juco J, **Mann KP**, Holden JT. 2004. Flow cytometry in the differential diagnosis of lymphocyte-rich thymoma from precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. *Am J Clin Pathol* 121:268-274, Feb.
24. Edelstein E, Gal AA, **Mann KP**, Miller JI Jr, Mansour KA. 2004. Primary solitary endobronchial plasmacytoma. *Ann Thorac Surg* 78:1448-1449, Oct. [Review]
25. Alvarado CS, Straus SE, Li S, Dale JK, **Mann K**, Le A, Lauer SJ. 2004. Autoimmune lymphoproliferative syndrome: a cause of chronic splenomegaly, lymphadenopathy, and cytopenias in children-report on diagnosis and management of five patients. *Pediatr Blood Cancer* 43:164-169, Aug.
26. Halkos ME, Miller JI, **Mann KP**, Miller DL, Gal AA. 2004. Thoracic presentations of post-transplant lymphoproliferative disorders. *Chest* 126:2013-2020, Dec.
27. Feldman AL, Berthold F, Arceci RJ, Abramowsky C, Shehata BM, **Mann KP**, Lauer SJ, Pritchard J, Raffeld M, Jaffe ES. 2005. Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. *Lancet Oncol* 6:435-437, Jun.
28. Rizzieri DA, Wadleigh M, Wikstrand CJ, **Mann KP**, Sen F, Peterson BL, Niedzwiecki D, Proia AD, Bigner DD. 2005. Tenascin and microvessel stromal changes in patients with non-hodgkins lymphoma are isolated to the sites of disease and vary in correlation to disease activity. *Leuk & Lymphoma* 46:1455-1462, Oct.

29. Arbiser JL, **Mann KP**, Losken EM, Cohen C, Reddy K, Kokko K, Pollack B, Fan CY, O'Reilly F. 2006. Presence of p16 hypermethylation and Epstein-Barr virus infection in transplant-associated hematolymphoid neoplasm of the skin. *J Am Acad Dermatol* 55:794-798, Nov. [Epub 2006 Sep 1]
30. Li S, **Mann KP**, Holden JT. 2008. Case Report: Composite small lymphocytic lymphoma and extramedullary myeloid tumor: A potential diagnostic pitfall. *Int J Clin Exp Pathol* 1:91-97, Jan. (www.ijcep.com/IJCEP704000, Jan 2008)
31. Kost CB, Holden JT, and **Mann KP**. 2008. Marginal zone B-cell lymphoma: A retrospective immunophenotypic analysis. *Cytometry B Clin Cytom* 74:282-286, Sep. (www.interscience.wiley.com, May 2008)
32. Murali S, Winton E, Waller EK, Heffner LT, Lonial S, Flowers C, Kaufman J, Arellano M, Lechowicz MJ, **Mann KP**, Khoury HJ, Langston AA. 2008. Long-term progression-free survival after early autologous transplantation for mantle cell lymphoma. *Bone Marrow Transplantation* 42:529-534, Oct. (www.nature.com/bmt, July, 2008)
33. Pullarkat ST, Pullarkat V, Kroft SH, Wilson CS, Ahsanuddin AN, **Mann KP**, Thein M, Grody WW, Brynes RK. 2009. Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia. *J Hematop* 2:27-33, Mar. [Epub 2009 Feb 10] (www.springerlink.com/openurl.asp?genre=article&id=doi:10.1007/s12308-009-0023-2, Feb. 11, 2009, Springer)
34. Schniederjan SD, Li S, Saxe DF, Lechowicz MJ, Lee KL, Terry PD, **Mann KP**. 2010. A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma. *Am J Clin Pathol* 133:718-726, May.
35. **Mann KP**. 2010. Gene patents: a view from the clinical laboratory. *Expert Rev Mol Diagn* 10:123-125, Mar.
36. **Mann KP**. 2010. Gene patents: perspectives from the clinical laboratory. *Mol Diagn Ther* 14:137-140.
37. Jima DJ, Zhang J, Jacobs C, Richards KL, Dunphy C, Choi WL, Au WY, Srivastava G, Czader, MB, Rizzieri D, Lagoo AS, **Mann KP**, Flowers CR, Khoury HJ, Sunay D, Naresh KN, Evens AM, Gordon LI, Luftig M, Friedman DR, Weinberg JB, Thompson M, Gill JI, Kahl BS, Gao Y, Xie B, Patel A, Wu H, ZHU J, Lugar PL, Lipsky PE, Dressman H, Chadburn A, Dave SS. 2010. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. *Blood* 116:e118-127, Dec.
38. Lima L, Bernal-Mizrachi L, Saxe D, **Mann KP**, Tighiouart M, Arellano M, Heffner L, McLemore M, Langston A, Winton E, Khoury HJ. 2011. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents and beyond. *Cancer* 117:1245-1252, Mar.

39. Jima DD, Patel A, Jacobs C, Liu Q, Richards KL, Dunphy CH, Choi WWL, Au WY, Srivastava G, Czader MB, Rizzieri DA, Lagoo AS, **Mann KP**, Flowers CR, Bernal-Mizrachi L, Naresh KN, Gordon LI, Evens AM, Luftig M, Gill JI, Greenough A, Zhang J, Hsi ED, Chadburn A, Dave SS. 2011. Alternative splicing is a major mechanism of gene regulation in diffuse large B cell lymphoma. (*Submitted 2011*)
40. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, **Mann KP**, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. 2012. The Genetic Landscape of Mutations in Burkitt Lymphoma. *Nat Genet* 44:1321-1325, Dec.
41. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar P, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, **Mann, KP** et al. 2013. Genetic Heterogeneity of Diffuse Large B Cell Lymphoma. *Proc Natl Acad Sci USA*. 110(4): 1398-1403, Jan.
42. Tong AKT, Schuster DM, **Mann KP**, Yan X. 2014. A Rare Presentation of Myocardial Plasmacytoma Assessed by FDG PET/CT. *Clin Nucl Med* 39(7): 643-645, Jul.
43. Ramachandiran S1, Adon A, Guo X, Wang Y, Wang H, Chen Z, Kowalski J, Sunay UR, Young AN, Brown T, Mar JC, Du Y, Fu H, **Mann KP**, Natkunam Y, Boise LH, Saavedra HI, Lossos IS, Bernal-Mizrachi L. 2014. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF- κ B pathway. *Int J Cancer*. doi: 136(10), 2341-2351. doi:10.1002/ijc.29301
44. Zhang L, Ramjit RT, Hill CE, Arellano M, Khoury HJ Rosado J, **Mann KP**. 2015. Clinical significance of quantitative monitoring and mutational analysis of BCR-ABL transcript in Philadelphia chromosome positive B lymphoblastic leukemia, Leukemia and Lymphoma. 1-6. doi:10.3109/10428194.2014.1003059
45. Maier CL, Fisher KE, Jones,HH, Hill CE, **Mann KP**, Zhang L. 2015. Development and Validation of CALR Mutation Testing for Clinical Diagnosis. *AJCP*. 144(5), 738-745. doi:10.1309/ajcpxpa83mvctsoq
46. Fisher KE, Zhang L, Wang J, Smith GH, Newman S, Schneider TM, Pillai RN, Kudchadkar RR, Owonikoko TK, Ramalingam SS, Lawson, DH, Delman KA, El-Rayes BF Wilson MM, Sullivan HC, Morrison, AS, Balci S, Adsay NV, Gal AA, Sica GL, Saxe DF, **Mann KP**, Hill CE, Khuri FR, Rossi MR. 2016. Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies, *Journal of Molecular Diagnostics*: 18 (2) Pages: 299-315

48. Guo, X., Koff, J., Moffitt, A., Cinar, M., Ramachandiran, S., Chen, Z., . . . Mann, K. (2017). Molecular impact of selective NFkB1 and NFkB2 signaling on DLBCL phenotype. *Oncogene*, 36(29):4224-4232. doi: 10.1038/onc.2017.90. Epub 2017 Apr 3.

b. Review Articles and Book Chapters:

1. Smith C, Lilly S, **Mann KP**, Livingston E, Myers S, Lyerly HK, Miralles GD. 1998. AIDS-related malignancies [Review]. *Annals of Medicine* 30:323-344.
2. Patel DD, Fong AM, **Mann KP**, Sundy JS, Whichard LP. 1997. CD166 Workshop: Tissue distribution and functional analysis of antibodies reactive with CD166, a ligand for CD6. In: *Leucocyte Typing VI*, T. Kishimoto, et al., Eds. 461-464.
3. **Mann KP**, McLendon RE, Provenzale J. 1999. Malignant lymphomas and hematopoietic neoplasms of the central nervous system. In: McLendon, RE, Bigner, DD, Bigner, SH and Provenzale, J, Eds: *Pathology of Tumors of the Central Nervous System: A Guide to Histologic Diagnosis*, London: Edward Arnold.
4. **Mann KP**, Saxe, DF. 2010. Molecular Pathology of Acute Myeloid Leukemias. In: Crisan, D, Ed: *Hematopathology: Genomic Mechanisms of Neoplastic Diseases*: Springer/ Humana Press.
5. **Mann KP**. 2012. Molecular Hematopathology. In: Hunt J, Ed: *Molecular Oncology, Surgical Pathology Clinics*, Vol 5(4): Elsevier, Inc
6. **Mann, KP** (2012). Molecular Pathology of Malignant Lymphoma. *Surg Pathol Clin*, 5(4), 879-902. doi:10.1016/j.path.2012.08.005
7. Li, S., Jaye, D. L., Bradley, K. T., Zhang, L., Saxe, D., Deeb, G., . . . **Mann, KP** (2017). Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms. *Archives of pathology & laboratory medicine*, 141(3), 341-354.

d. Other Publications:

1. Klyce SD, Palkama KA, Marshall WS, Huhtaniitty S, **Mann KP**. 1981. Evidence for serotonergic receptors in corneal epithelium. *Invest Ophthalmol Vis Sci* 20 (ARVO Suppl) 194.
2. **Mann KP**. 1986. The identification and characterization of an Epstein-Barr virus protein found in the plasma membrane of latently infected cells. Ph.D. Dissertation. Sackler School of Graduate Biomedical Sciences, Tufts University.
3. **Mann KP**, Weiss EA, Nevins JR. 1991. Role of polyadenylation factors, particularly the downstream specific factor, in selective poly(A) site utilization. Presented at Cold Spring Harbor Laboratories meeting on RNA Processing.

4. **Mann KP**, Hall B, Kamino H, Borowitz MJ, Ratech H. 1994. Neutrophil rich Ki-1 positive anaplastic large cell malignant lymphoma. *Mod Pathol* 7:114a.
5. **Mann KP**, Liu J, DeCastro CM, Moore JO, Bigner S, Traweek ST. 1995. CD56 (N-CAM) expression in acute non-lymphoid leukemia (ANLL) and Myelodysplastic syndrome (MDS). *Mod Pathol* 9:116a.
6. DeCastro CM, Moore JO, Traweek T, **Mann KP**. 1995. Bone marrow necrosis secondary to hydroxyurea treatment for the retinoic acid syndrome. *Blood* 86(suppl 1): 755a.
7. Rizzieri DA, DeCastro CM, **Mann KP**, Moore JO. 1995. T cell lymphoblastic leukemia with mediastinal mass and c-kit expression. *Blood* 86(suppl 1):777a.
8. **Mann KP**, Fong AM, Patel DD. 1996. Expression of CD6 and CD6L (ALCAM) in hematopoietic neoplasms. *Cytometry* 26:343.
9. **Mann KP**, Fong AM, Patel DD. 1996. Expression of CD6 and its ligand, ALCAM, on hematopoietic malignancies of the myeloid and B-cell lineages. *Tissue Antigens* 48:AS403.
10. McLendon RE, Friedman AH, Provenzale JM, Brown MT, **Mann KP**. 1996. Castleman's disease (plasma cell variant) confined to the leptomeninges. *J Neuropathol Exp Neurol* 55: 76.
11. Liu K, Liu J, **Mann KP**, McLendon R, Traweek ST. 1997. B-cell clonality in Castleman's disease, plasma cell type. *Lab Invest* 76:752.
12. Rizzieri DA, Wikstrand CJ, **Mann KP**, Sen F, Proia AD, Niedzwiecki D, Bigner DD, Vredenburgh J. 1999. Markers of angiogenesis, factor VIII and tenascin, correlate with disease activity in patients with non-Hodgkin's lymphoma. *Blood* 94:4339.
13. Wadleigh M, Niedzwiecki D, Davis P, Payne N, Sen F, **Mann KP**, Proia A, Hollis D, Rizzieri DA. 2001. Increased microvessel density in non-Hodgkin's lymphoma (NHL) is localized to the site of disease changes in accordance with disease response. *Blood* 98:4669.
14. Djalilvand A, Hill CE, **Mann KP**. 2005. Comparison of Analysis Methods for Identification of T Cell Clonality Using PCR with Capillary Electrophoresis. *Modern Path* 18:227a.
15. Kost CB, Holden JT, **Mann KP**. 2005. Marginal Zone Lymphoma: A Retrospective Immunophenotypic Analysis. *Modern Path* 18:238a.
16. Park SI, Bell J, **Mann KP**, Holden JT. CD13 Expression by IGM-Producing Low Grade B-Cell Lymphomas. *Modern Path* 18:245a.

17. Bradley KT, Rosado J, **Mann KP**. 2008. Evaluation of Signature® Primers and Signature® Probes (ASR) for Detection of Leukemia-Associated Translocations. AMP Abstracts. J Molecular Diagnostics 10:583, Nov. (<http://jmd.amipathol.org>)
18. Cole JM, Sinha R, Flowers C, **Mann K**. 2008. Clinical Laboratory Validation of InVivoScribe Lymphotrak™ IgH TrackTwo™ Assays for the Detection of Minimal Residual Disease in CLL/SLL. AMP Abstracts. J Molecular Diagnostics 10:584, Nov. (<http://jmd.amipathol.org>)
19. Jacobs CL, Lagoo AS, Dash RC, Raji A, Evens AM, Winter JN, Gordon LI, Kahl BS, Czader M, Srivastava G, **Mann KP**, Gill J, Rizzieri D, Dave S. 2008. MicroRNAs Distinguish Burkitt Lymphoma from the Molecular Subsets of Diffuse Large B Cell Lymphoma. ASH Abstracts. Blood 112:1151, Nov. (www.bloodjournal.org)
20. Khoury HJ, Lima L, Saxe D, **Mann KP**, Arellano M, Heffner L, Bernal-Mizrachi L, McLemore M, Langston A, Winton E. 2009. Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed? J Clin Oncol 27:15s, (suppl; abstr 7064).
21. Lima L, Assouline SE, Saxe D, **Mann K**, McLemore M, Souza L, Arellano M, Winton EF, Bernal-Mizrachi L, Khoury HJ. 2009. Does pre-imatinib (IM) fluorescence in situ hybridization (FISH) predict myelosuppression and outcomes in chronic myeloid leukemia (CML)? J Clin Oncol 27:15s, (suppl; abstr 7071).
22. Carter AB, Schniederjan S, **Mann, K**. 2009. Software for the Laboratory: The Blood and Bone Marrow Counter. (Abstract) Arch Pathol Lab Med 133:1150, July.
23. Ramjit RT, Hill CE, Khoury HJ, Lima L, **Mann K**. 2010. B-Lymphoblastic Leukemia/ Lymphoma with t(9;22)(q34;q11.2): Monitoring of BCR-ABL1 transcript level by Q-RT-PCR, correlation with treatment and other methods of MRD monitoring. J Molecular Diagnostics 12:869.
24. Jacobs CL, Patel A, Jima D, Liu Q, Greenough A, Zhang J, Dunphy C, Richards K, Choi W, Srivastava G, Au W, Evens AM, Gordon LI, Czader M, Rizzieri DA, Lagoo AS, **Mann KP**, et al. 2010. Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma. ASH Annual Meeting Abstracts. 116(21):803, Nov.
25. Love CL, Jima D, Zhang J, Grubor V, Miles RR, Dunphy CH, Richards KL, Choi WWL, Au WY, Srivastava G, Chadburn A, Gordon LI, Evens AM, Hsi ED, Czader M, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, **Mann KP** et al. 2011. Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma. Blood. 118(21): 199-200.

26. Gibson J, Aziz N, Bayrak-Toydemir P, Cotter P, Farkas DH, Ferreira-Gonzalez A, Furtado M, Greiner TC, Hambuch T, Klein RD, Leonard DGB, Lyon E, **Mann KP**, et al. 2011. The Association for Molecular Pathology's Approach to Supporting a Global Agenda to Embrace Personalized Genomic Medicine. *J Mol Diag.* 13(3): 249-251.
27. Husman AL; Toscano M; Chandler KL, Holden JA, **Mann, KP**. 2012. Plasma Cell Myeloma Evaluation by Flow Cytometric Immunophenotyping: Aberrant Antigen Expression and Correlation with Cytogenetic/FISH Abnormalities. *Modern Pathology* 25 (Sup) 342A.
28. Hinrichs, BH, Carter, AB, Hill CE, Liu Y, Switchenko J, **Mann KP**, 2012. Utility of Electronic Synoptic Reporting for Retrieval of Molecular Results. *J Mol Diag.* 14(6): 732.
29. Ramjit RT, Stowell SR, Hill CE, Nabila S, Zhang L, **Mann KP**, 2012, Comparison of the Performance Characteristics of Two Commercially Available Real-time RT-qPCR Assays for the Quantification of BCR/ABL1 Transcripts on the WHO International Scale. *J Mol Diag.* 14(6):662.
30. Smith, GH, Caltharp S, Saxe DF, **Mann KP**, Hill CE, Carter AB. Retrieving Molecular and FISH Data from Pathology Reports: A Comparison of Synoptic and Natural Language Search Tools in a Commercial Anatomic Pathology Laboratory Information System Abstracts: *Pathology Informatics* 2012. *J Pathol Inform* 2012;3:37
31. Rossi, M., Appin, C., Bellail, A., **Mann, K.**, Saxe, D., Hill, C., . . . Brat, D. (2013). Genomic Characterization of Diffuse Astrocytoma by SNP-CN Arrays and Hot-Spot Mutation Sequencing. Paper presented at the JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY.
32. Koff, J. L., Guo, X., Ramachandiran, S., Switchenko, J. M., Mosunjac, M. B., Neill, S. G., Mann, K. . . . Bernal-Mizrachi, L. (2014). Putting the 'Activate' in Activated B Cell-like Diffuse Large B Cell Lymphoma: A Role for the Noncanonical NF- κ B Pathway. *Clinical Lymphoma, Myeloma and Leukemia*, 14, S143.
33. Flowers, CR; Link, BK; Nastoupil, LJ; McDonnell, TJ; Kahl, BS; Vij, KR; Casulo, C; Friedberg, JW; Burack, R; Lossos, IS; Thompson, CA; Yost, KJ; Vega, F; Syrbu, S; Martin, P; Leonard, JP; Inghirami, G; Bernal-Mizrachi, L; **Mann, KP**; et al. The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. *Blood* 132 S1, : NOV 29 2018

26. References

Available on request